



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
February 5, 2021
9:00 A.M.

Virtual - See information below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of November 6, 2020
4. Election of Officers - CY2021
5. Preferred Drug List: Therapeutic Class Re-Review
 - a) Respiratory
 - i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
 - ii. Antiviral Monoclonal Antibodies
 - iii. Beta Adrenergics and Corticosteroids
 - iv. Beta Agonists
 - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
 - vi. Leukotriene Receptor Antagonists
 - vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
 - viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
 - ix. Oral Inhaled Glucocorticoids



- x. Phosphodiesterase-4 Inhibitors
- xi. Pulmonary Antihypertensives
- b) Anti-Infectives
 - i. Antivirals - Anti-Herpetic Agents
 - ii. Antivirals - Influenza Agents
 - iii. Cephalosporins - 3rd Generation
 - iv. Fluoroquinolones
 - v. Hepatitis C Agents
 - vi. Macrolides
 - vii. Ophthalmic Antibiotics
 - viii. Ophthalmic Antibiotics/Corticosteroid Combinations
 - ix. Oral Non-Systemic Antifungals
 - x. Otic Antibiotics
 - xi. Systemic Antifungals
 - xii. Topical Antifungals
 - xiii. Topical Antivirals
 - xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
 - xv. Vaginal Antimicrobials
- c) Cardiovascular
 - i. Angiotensin-Converting Enzyme (ACE) Inhibitors
 - ii. ACE Inhibitor Combinations
 - iii. Alpha Adrenergic Blockers
 - iv. Angiotensin II Receptor Antagonists (ARBs)
 - v. ARB Combinations
 - vi. Beta Adrenergic Blockers
 - vii. Beta Adrenergic Blockers with Diuretics
 - viii. Calcium Channel Blockers (CCBs)
 - ix. CCBs with HMG-CoA Reductase Inhibitors
 - x. Miscellaneous Cardiac Agents
- d) Lipotropics
 - i. Bile Acid Sequestrants

- ii. Fibrin Acid Derivatives
 - iii. HMG-CoA Reductase Inhibitors
 - iv. Lipotropics
 - e) Antimigraine Agents
 - f) Electrolyte Depleters
 - g) Multiple Sclerosis Agents
6. New Business
 7. Public Comment
 8. Other Business
 9. Adjourn

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

https://teams.microsoft.com/l/meetup-join/19%3ameeting_OGQ5Y2ZhODItNWNjOC00YmEyLTg4ZjMtODg0N2U3ODkwNjRh%40thread.v2/0?context=%7b%22Tid%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22Oid%22%3a%2253df74d0-e68c-46fe-81f5-fac4b0bd8ef8%22%7d

Or call in (audio only)

[+1 952-222-7450](tel:+19522227450),550964097# United States, Bloomington

Phone Conference ID: 550 964 097#